December 8, 2017

December 08, 2017

Myriad Genetics Breast Cancer Risk SNP Score Improves Upon Traditional Measures, Study Shows

360 DX – Dec. 7
When clinicians first learned about the increased risks conferred by BRCA1 and BRCA2, many were reluctant to recommend their patients take preventive action, such as mastectomies and oophorectomies, recalled Lancaster, who before joining Myriad directed the Center for Women's Oncology at Moffitt Cancer Center.

Ovarian Function, Fertility Potentially Protected By Hormone Analog For Women Treated With Chemo

Targeted Oncology – Dec. 7
To develop more conclusive clinical evidence, Lambertini and his colleagues performed meta-analysis on 5 randomized clinical trials—PROMISE-GIM6, POEMS/SWOG S0230, Angelo Celtic Group OPTION, GBG-37 ZORO, and a Moffitt Cancer Center-led trial—in which premenopausal women with early-stage breast cancer were randomly assigned to chemotherapy alone (n = 437) or chemotherapy with concurrent GnRHa (n = 436). Also shared on Cure Magazine, Medical Xpress, ASCO Post and OncLive.

Temporary ovarian suppression preserves fertility during chemotherapy

Healio – Dec. 7
Lambertini and colleagues conducted a meta-analysis that included data on 722 premenopausal women (median age, 38 years) with early-stage breast cancer randomly assigned to chemotherapy alone (n = 359) or with concurrent GnRHa (n = 363) included in PROMISE-GIM6, POEMS/SWOG S0230, Angelo Celtic Group OPTION, GBG-37 ZORO and a Moffitt Cancer Center-led trial.

Can Temporary Ovarian Suppression During Breast Cancer Treatment Preserve Fertility?

Cancer Network – Dec. 7
The five clinical trials studied were PROMISE-GIM6, POEMS/SWOG S0230, Anglo Celtic Group OPTION, GBG-37 ZORO, and a Moffitt Cancer Center–led trial.

TUM Researchers Developing Database of Kinase Inhibitor Target Profiles

GenomeWeb – Dec. 7

For instance, in an October study in Nature Chemical Biology, researchers at the H. Lee Moffitt Cancer Center and Research Institute used an approach similar to that employed by Küster and his colleagues to explore the molecular mechanisms underpinning the function of the anaplastic lymphoma kinase inhibitor ceritinib in lung cancer and found that several off-target interactions are key to that drug's activity.

Ovarian cancer could be next application for CAR T-cell therapy

Managed Healthcare Executive – Dec. 6
While CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors. That’s why Amit Kumar, PhD, president and CEO at ITUS Corporation, a San Jose, California-based cancer-focused biotechnology company, is working with researchers at Moffitt Cancer Center to determine if this therapy can be beneficial to women with ovarian cancer.

Rookies Surprise Hometown Grant Recipients – Dec. 6
They have also spent their off day with children at Metropolitan Ministries, and visited with patients and their families at Moffitt Cancer Center.

Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology

Markets Insider – Dec. 5
The study, Percutaneous Hepatic Perfusion with Melphalan in Uveal Melanoma: A Safe and Effective Treatment Modality in an Orphan Disease, was conducted by researchers from Moffitt Cancer Center in Tampa, FL and the University Hospital Southampton in the United Kingdom.

Men With HPV Are 20 Times More Likely To Be Reinfected After One Year

Science Magazine – Dec. 5
The study, "Recurring infection with ecologically distinct human papillomavirus (HPV) types explains high prevalence and diversity," was supported by the National Institutes of Health. Additional authors include Edward Baskerville from the University of Chicago; Vanja Dukic and Anna Giuliano from the H. Lee Moffitt Cancer Center; Luisa Villa from Universidade de Sao Paulo, Brazil; and Eduardo Lazcano-Ponce from Instituto Nacional de Salud Publica, Cuernavaca, Mexico.

Jeff Vinik plans new venture capital fund and innovation hub at Water Street Tampa

Tampa Bay Times – Dec. 5
Vinik said he likes existing organizations like the Tampa Bay Wave, new initiatives like the Florida-Israel Business Accelerator and long-term efforts like Tampa !p, an innovation effort involving the University of South Florida, Moffitt Cancer Center, Florida Hospital Tampa, Busch Gardens and University Mall.

Moffitt Cancer Center Names Dr. Louis Harrison Vice President, Chief Partnership Officer

Press Release Point – Dec. 5
Louis B. Harrison, M.D., has assumed additional responsibilities at Moffitt Cancer Center as Vice President, Chief Partnership Officer. In this capacity, he will work to develop multifaceted partnership and strategic alliances that advance the cancer center’s strategic goals and increase patient access to the institution.

Patent Issued for Bone Fusion System

Pharmacy Choice – Dec. 5
The patent's assignee for patent number 9820788 is H. Lee Moffitt Cancer Center and Research Institute Inc. (Tampa, FL).

Polk County people in medicine

The Lakeland Ledger – Dec. 5
Dr. Paramjeet Kaur has joined Baycare Medical Group’s specialist clinic, 199 Ave. B NW, Suite 310, Winter Haven, as a breast surgeon. Board certified in surgery and an author contributing to several medical journals, Kaur received her medical degree in India, general surgery internship in Pennsylvania, a general surgery residency in West Virginia and a fellowship in surgical breast oncology at Moffitt Cancer Center in Tampa. 

Could math help defeat cancer? Moffitt is betting it will

Tampa Bay Times – Dec. 5

Department chair Alexander Anderson, who came to Moffitt from the University of Dundee in Scotland, said he struggled in the past to convince doctors that math could help in the battle against cancer. "They didn’t want to talk to me," he said. But at Moffitt, "they realized the traditional perspective wasn’t working," he said. "They needed to consider other things, like physical sciences, that could factor into cancer."


Moffitt Cancer Center treats first patient with newly approved CAR T-cell therapy

Healio – Dec. 4
Moffitt Cancer Center treated the first patient commercially in the United States with axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy.

The infusion occurred Nov. 27, according to a Moffitt-issued press release. Also seen on

Co-workers and Vineyarders rally around maternity nurse

MV Times – Dec. 4
“I’m just completely overwhelmed,” Ms. Furtaw said Monday, shortly after arriving in Florida where she will undergo treatment at the Moffitt Cancer Treatment Center in Tampa. Her friend has taken time away from work to drive her to and from appointments. 

USC professor tackles cancer one gene at a time

Daily Gamecock – Dec. 3
While an undergraduate at the University of South Florida, Phillip Buckhaults would often eat lunch in the Moffitt Cancer Center at USF’s medical school. He watched, day in and day out, as sick children would wheel their IV’s into the cafeteria to eat while receiving chemotherapy. This left a lasting mark on him. It was here that he was inspired to take up the fight against cancer, the "emperor of all maladies." 

What It Means When A Woman Has Uneven Breasts – Dec. 2
“It is actually more common for women to have different breast shape and size than absolutely symmetrical breasts,”  Dr. Jennifer Widner recently told Self Magazine. Nazanin Khakpour, M.D., F.A.C.S., a surgical oncologist specializing in breast cancer at Moffitt Cancer Center, added, “They are sisters, not twins.”


Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.